Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Public ClinicalTrials.gov record NCT01416428. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the maximum tolerated dose (MTD), activity, and safety of oprozomib in patients with hematologic malignancies.
Study identification
- NCT ID
- NCT01416428
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 210 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 15, 2011 (Actual)
- Primary completion
- Aug 8, 2016 (Actual)
- Completion
- Aug 12, 2019 (Actual)
- Last update posted
- Nov 8, 2022
2011 – 2019
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Scottsdale | Scottsdale | Arizona | — | — |
| Pacific Cancer Care | Salinas | California | — | — |
| Colorado Blood Cancer Institute | Denver | Colorado | — | — |
| Mayo Clinic | Jacksonville | Florida | — | — |
| Winship Cancer Institute, Emory University | Atlanta | Georgia | — | — |
| Rush University Medical Center | Chicago | Illinois | — | — |
| University of Chicago Medical Center | Chicago | Illinois | — | — |
| University of Maryland, Greenebaum Cancer Center | Baltimore | Maryland | — | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | — | — |
| Mass General Hospital | Boston | Massachusetts | — | — |
| Virginia Piper Cancer Institute | Minneapolis | Minnesota | — | — |
| Mayo Clinic | Rochester | Minnesota | — | — |
| Washington University School of Medicine Division of Oncology | St Louis | Missouri | — | — |
| John Theurer Cancer Center at Hackensack University | Hackensack | New Jersey | — | — |
| Hematology Oncology of Northern New Jersey | Morristown | New Jersey | — | — |
| New York Oncology Hematology | Albany | New York | — | — |
| Mount Sinai Medical Center | New York | New York | — | — |
| Sarah Cannon Research Institute / Tennessee Oncology, PLLC | Nashville | Tennessee | — | — |
| Columbia Basin Hematology and Oncology | Kennewick | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01416428, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 8, 2022 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01416428 live on ClinicalTrials.gov.